

Diabetic Neuropathic Pain Therapeutic Pipeline Market Review, H1 2016

Diabetic Neuropathic Pain - Pipeline Review, H2 2016

PUNE, INDIA, August 30, 2016
/EINPresswire.com/ -- Summary

'[Diabetic Neuropathic Pain](#) - Pipeline Review, H2 2016', provides an overview of the Diabetic Neuropathic Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Complete report details @ <https://www.wiseguyreports.com/reports/619302-diabetic-neuropathic-pain-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619302-diabetic-neuropathic-pain-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
 - The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
 - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
 - The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects
 - The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
 - The report summarizes all the dormant and discontinued pipeline projects
 - The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain
- Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
 - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
 - Identify potential new clients or partners in the target demographic
 - Develop strategic initiatives by understanding the focus areas of leading companies
 - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
 - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
 - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619302->

[diabetic-neuropathic-pain-pipeline-review-h2-2016](#)

Key points in table of content

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Neuropathic Pain Overview 9

Therapeutics Development 10

Pipeline Products for Diabetic Neuropathic Pain - Overview 10

Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11

Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12

Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 14

Diabetic Neuropathic Pain - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Diabetic Neuropathic Pain - Products under Development by Companies 18

Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 19

Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 20

APT Therapeutics, Inc. 20

Astellas Pharma Inc. 21

BioDelivery Sciences International, Inc. 22

Bristol-Myers Squibb Company 23

Centrexion Therapeutics Corp 24

Chromocell Corporation 25

Daiichi Sankyo Company, Limited 26

Grunenthal GmbH 27

Hydra Biosciences, Inc. 28

Immune Pharmaceuticals Inc. 29

Laboratorios Del Dr. Esteve S.A. 30

Lohocla Research Corporation 31

Novaremed 32

PeriphaGen, Inc. 33

Pharmaleads SA 34

Prismic Pharmaceuticals, Inc. 35

Relmada Therapeutics, Inc. 36

Sphaera Pharma Pvt. Ltd. 37

Theravasc, Inc. 38

Diabetic Neuropathic Pain - Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Combination Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(amitriptyline + ketamine hydrochloride) - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
(diclofenac sodium + triclocarban) - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
APT-102 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
AS-1069562 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CC-8464 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
cebranopadol - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
clonidine hydrochloride - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
CNTX-6016 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
EC-5026 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
filgrastim - Drug Profile 65
Product Description 65
Mechanism Of Action 65

R&D Progress 65
GERP-001 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
HX-100 - Drug Profile 67

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619302

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/342367004>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.